Bioactivity | Beloranib hemioxalate is a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor. Beloranib hemioxalate decreases food intake, body weight, fat mass, and the size of adipocytes[1][2][3][4]. |
CAS | 529511-79-3 |
Formula | C29H41NO6.1/2C2H2O4 |
Molar Mass | 1089.32 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Elfers CT, Roth CL. Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity. Endocrinology. 2017;158(1):41-55. [2]. Kim YM, An JJ, Jin YJ, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007;38(4):455-465. [3]. Lee HS, Choi WK, Son HJ, et al. Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Arch Pharm Res. 2004;27(2):265-272. [4]. Kim EJ, Shin WH. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biol Pharm Bull. 2005;28(2):217-223. |